To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, join Dr. Robert Poolman on Tuesday, January 10, 2023 for a presentation on integrating disparate datasets to maximize healthcare benefits for patients during 2023 Fierce JPM Week. For more information, visit: https://www.fiercejpmweek.com/fiercejpmweek/jpmweek-person-agenda.
Methodology for the Clarivate Drugs to Watch 2023 Report
Increasingly, companies are targeting smaller patient populations with more targeted drugs, many of which will garner less revenue than the mass-market drugs that have traditionally formed the bread and butter of large pharmas but which stand to greatly advance patient care. Accordingly, Clarivate revised its methodology to recognize late-stage developmental therapeutics of clinical and commercial notes.
To identify this year’s Drugs to Watch, Clarivate drew from the expertise of over 160 analysts covering hundreds of diseases, drugs and markets and eleven integrated data sets that span the R&D and commercialization lifecycle, including:Cortellis Competitive Intelligence™, Disease Landscape & Forecast, BioWorld™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Generics Intelligence™, Cortellis Deals Intelligence™, Access & Reimbursement payer studies, Clarivate Real World Data and Analytics, Web of Science™Derwent Innovation™ and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2022 were selected for analysis, including those pursuing new indications that could be particularly impactful; drugs launched prior to 2022 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2027. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors, and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers. Please note that Clarivate analysts generated the data shown in this report prior to December 15, 2022. The Drugs to Watch 2023 Report and the treatments referenced in this release are based on Clarivate’s current expectations based on existing data, but actual results derived from the drugs named in the report and here may differ significantly.
Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerating innovation, Clarivate’s end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions.
Clarivate™ is a global leader in providing solutions to accelerate the pace of innovation. Our bold mission information and insights that reduce the time from new ideas to life-changing inventions in the areas of Academia & Government, Life Sciences & Healthcare, Professional Services and Consumer Goods, Manufacturing & technology. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.